ClinicalTrials.gg
RecruitingNCT03913962HERCCULEUpdated Nov 9, 2026

Health and Exercise Response in Children With Chronic and Auto-immune Pathologies

An interventional study of indirect calorimetry in Juvenile Idiopathic Arthritis, Diabetes and Inflammatory Bowel Disease, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.
Updated Nov 9, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.

Planned enrollment
Largest of 50
300 · median 61
Started
2019
with 4 others
No phase
13 of 71
4 open now
Primary completion
2028-12
later than 15 of 20 live
Registered
41st of 71
by date
Lead sponsor
6 of 71
University Hospital, Clermont-Ferrand

Among the 71 studies in Arthritis, Juvenile with a site in France, this one has the largest planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2019, is one of 13 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 41st registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Arthritis, Juvenile with a site in France, or all of them as a file.
02

Study summary

The aim of the present project is to assess the effects of the chronic diseases and their associated treatments chronic paediatric diseases (CPD), to further understand their impact on physical fitness for public health perspectives. This is an innovative approach in the treatment of chronic paediatric diseases . This project should yield results that help improving treatments for children and adolescents with chronic paediatric diseases throughout physical activity as therapy, reduced pain, fatigue and inflammation, and improvement in physical fitness and life quality. The originality and novelty of this project is to combine architectural, functional and metabolic components of skeletal muscle to further understand the impact of chronic paediatric diseases as a function of treatment, disease activity and maturation status (prepubertal, pubertal or post pubertal).

This study will aim at assessing muscular function (force production capacity and fatigability) in specific or ecologic situations so as to get information about muscle functioning on isolated muscle group (here knee extensors) or during whole body exercise. Moreover, results arising from muscle architecture or quality will allow understanding the decrease in strength or endurance reported in the literature. The data collected will allow us to further understand the impact of the disease on structural, functional and metabolic parameters. Finally, the understanding of these alterations will provide information enabling to establish recommendations in physical activity (PA) to reduce or even counter the effect of the chronic inflammation and prevent at long-term overweight and cardiovascular risks.

The long-term objective is to contribute establishing recommendations or guidelines for prescribing physical activity during medical therapy. Values obtained in pathological children will be compared to those of control children matched for gender and maturation.

Read the detailed description

Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.

Patients will perform physical tests to provide information about their physical fitness (body composition, metabolic flexibility, muscle strength and fatigue, bone mineral density), which will be compared to age- and gender-matched healthy controls. Patients will also complete blood tests to provide information about their inflammatory state to best understand physiological disorders and allow a better classification of the disease status.

  1. Metabolic flexibility assessment

    After sitting quietly for 20 min, subjects will perform a graded exercise test to volitional fatigue on an electromagnetically braked cycle ergometer with continuous gas collection and heart rate monitoring. In all subjects, when the Respiratory Exchange Ratio will be ≥1.00, indicating zero fat oxidation, the work rate will be increased by the same increments at 1-min intervals until volitional fatigue. O2 consumption (VO2) peak will be considered maximal when the Respiratory Exchange Ratio will be ≥1.05 and the subject will achieve his age-predicted maximal heart rate [heart rate maximum: (220 - age)]. Indirect calorimetry, as will be used in this study, is the standard method to quantify substrate oxidation rates at rest and during exercise. O2 consumption (VO2) and CO2 production (VCO2) will be averaged over the final 1 min of each work rate, and the results of this test will be used to calculate fat oxidation over a wide range of exercise intensities for each subject with the equations:

    Lipids (mg.min-1) = 1.6946 x VO2 - 1.7012 x VCO2 and CHO (mg.min-1) = 4.585 VCO2 - 3.2255 VO2.

  2. Muscle architecture Subjects will be lied on a massage table, muscle relaxed. Ultrasound will be used on vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) to assess muscle architecture. The muscle belly will be measured according to Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles (SENIAM) recommendations. Muscle thickness (the distance between superior and inferior aponeurosis) and fascicule angle (the angle formed by muscle fascicule and the inferior aponeurosis) will be measured for each muscle.
  3. Muscle quality Subjects will sit on an adjustable seat. The right tight will be placed into the antenna of the peripheral quantitative tomography, so that the femoral condyles are aligned with the laser. An antero-posterior scout-view will be performed to detect junction between tibial tray and the femur, which matched with the starting position of the measurement. Then, a measure will be performed at 40% of the length between the greater trochanter and the mid-patella of the right leg. Muscle cross sectional area (CSA) and intramuscular adipose tissue (IMAT) will be assessed. The measurements will be performed by the same investigator to avoid any inter-individual bias.
  4. Muscle function

    o Vertical jump height: Subjects will have to perform a series of vertical jumps. Subjects will perform two squat jumps (SJ) and two counter movements jumps (CMJ) using an OptoJump following standardised guidelines. For SJ, subjects will have to flex their knee at 90° with the hand on the hip to avoid any counter movements induced by the upper limbs. Subjects will have to maintain the position for 3-s. The guidelines for CMJ will be similar, but without short break between standing and flexing positions. For both exercises, subjects will have to jump as high as possible. Vertical jump height will be calculated according the formula where T is time flight duration and g the acceleration of 9.81 m.s-2 of gravity.

    o Maximal voluntary strength: Subjects will sit on an isokinetic dynamometer with a hip angle of 40° (0°= standing position). Upper body will be strapped on the chair back and subjects will have to grip the chair to avoid any counter-movements. Their right ankle will be strapped and connected to a force sensor. After a standardised warm up consisting of repeating isometric contractions at increasing intensities, patients will have to perform maximal voluntary isometric contractions (MVIC). MVIC will be performed at different randomized joint angles (29°, 66°, 76°, 87° and 103° [0° = full extension]) to determine the optimal angle producing maximal strength. Two measurements will be performed at each angle to check the reproducibility. A third trial will be performed if the difference between both measurements is higher than 5%. Subjects will be vigorously encouraged to produce maximal voluntary strength during isometric contractions. Root Mean Square (RMS) values will be calculated from the electromyographic (EMG) activity recorded on VL, VM and RF.

  5. Muscle fatigue Muscle fatigue will be assessed with the same method as previously described. For this test, patients will have to maintain a force level corresponding to 50% MVIC to avoid any knee pain. The exercise will be stopped when subjects will be unable to maintain the force level more than 3-s despite vigorous encouragements. Time duration to task failure will be measured.
  6. Bone micro-architecture Bone micro-architecture will be assessed through bone mineral density, trabecular and cortical density. This measurement will be performed in the same time that muscle quality assessment by pQCT. Patients will be placed in the same position. Two measurement will be done using pQCT at 20% and 40% of the tight. Micro-architectural parameters (trabecular and cortical density) will be calculated.
  7. Body composition Body composition will be assessed by Dual-energy X-ray absorptiometry. Fat and fat-free mass, and bone density will be measured for the whole body and segments (arm, leg and trunk).
  8. Biology Blood samples will be drawn once a year for patients and once for controls. Blood samples will allow to assess NFS (blood formul numeration), ionogramme, CRPus, VS, total bilirubin, ASAT, ALAT, GGT, PAL, glycaemia, total cholesterol -HDL-LDL, triglycerid, TSH, T4, adiponectin et leptin. Lipidomic, Cytokines and their receptors, calgranulins and MicroARNs will be also assessed thereafter.
03

Conditions studied

  • Juvenile Idiopathic Arthritis
  • Diabetes
  • Inflammatory Bowel Disease
  • Cancer Survivor
  • Anorexia Nervosa

Keywords

  • Paediatric
  • Auto-immunity
  • Treatment
  • Physical Activity
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • for patients:
  • Aged between 6 and 18-year-old
  • Male or female
  • Presenting a chronic pathology / having a treatment which is known to alter muscle mass and function, metabolism and body composition
  • Included in the active list of the hospital centre of Clermont-Ferrand
  • Free and of the holders of parental authority and the patient
  • Affiliated with the social security system for control:
  • Aged between 6 and 18-year-old
  • Male or female
  • Free and informed consent of the holders of parental authority and the patient
  • Affiliated with the social security system

Exclusion criteria

Exclusion Criteria:

  • for patients:
  • Treatment by systemic corticoids (>1 week in the 30 days before test)
  • to sport practice
  • Active infection for control:
  • Contraindication to sport practice
  • Chronic pathology susceptible to alter muscle mass and function, metabolism and body composition
  • Treatment susceptible to alter metabolism
  • Active infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Patient

    Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor

    Other: indirect calorimetry

  • Active comparator
    Control

    healthy children sex- and age-matched

    Other: indirect calorimetry

Interventions

  • Otherindirect calorimetry

    Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.

06

What researchers measure

Primary outcomes

  1. Maximal lipid oxidation rate during submaximal incremental exercise

    Percentage variation of the maximal strength rate during isometric contraction between pathological and healthy children

    Time frame: at first test (at day 1)

Secondary outcomes

  1. Maximal strength during isometric contraction

    Percentage variation of the maximal strength rate during isometric contraction between pathological and healthy children

    Time frame: at day 1

  2. Muscle architecture

    muscle cross sectional area (mm2) evaluated by peripheral Quantitative Computed Tomography (pQCT)

    Time frame: At 6 months

  3. Body composition

    fat mass (g.cm²) evaluated by Dual-energy X-ray absorptiometry

    Time frame: At 6 months

  4. Maximal muscular strength

    maximal strength of knee extensors

    Time frame: At day 1

  5. Muscular fatigue

    Percentage variation of time to task failure duration during isometric contraction between pathological and healthy children.

    Time frame: at 6 months

  6. Blood sample IL-17

    blood level of inflammation markers (IL-17)

    Time frame: At day 1

  7. Blood sample CRP

    blood level of inflammation markers (CRP)

    Time frame: At day 1

  8. Blood sample IL-6

    blood level of inflammation markers (IL-6)

    Time frame: At day 1

  9. Blood sample TNF - a

    blood level of inflammation markers (TNF - a)

    Time frame: At day 1

  10. Blood sample IL-10

    blood level of inflammation markers (IL-10a)

    Time frame: At day 1

  11. Blood sample INF

    blood level of inflammation markers (INF)

    Time frame: At day 1

  12. Blood sample calprotectin

    blood level of inflammation markers (calprotectin)

    Time frame: At day 1

07

Study locations

1 of 1 sites recruiting
  • Chu Clermont-Ferrand
    Clermont-Ferrand, 63003, France
    Recruiting
    • Lise LACLAUTRE · Contactdrci@chu-clermontferrand.fr · 04 73 75 49 63
    • Etienne MERLIN · Principal investigator
    • Justyna KANOLD · Sub investigator
    • Daniel TERRAL · Sub investigator
    • Stéphane ECHAUBARD · Sub investigator
    • Nicolas KARON · Sub investigator
    • Corinne BORDERON · Sub investigator
    • Florentina IFSAN · Sub investigator
    • Eric DORE · Sub investigator
    • Isabelle PETIT · Sub investigator
08

References and documents

Publications

  • Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent Children With Type 1 Diabetes Mellitus. Front Physiol. 2021 Apr 9;12:664211. doi: 10.3389/fphys.2021.664211. eCollection 2021. PubMed 33897473 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2028, 115 months after the start.

Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 115 months is above that.

Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2019
First posted
Apr 12, 2019
StartActual
May 2, 2019
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C… PubMed 33897473 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Publications Results publication added: Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C… PubMed 33897473 ↗
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03913962
Collaborators
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques, INSERM CIC 1405
Responsible party
Sponsor
First posted
Apr 12, 2019
Start date
May 2, 2019
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Lise LACLAUTRE
Contact
drci@chu-clermontferrand.fr
04 73 75 49 63
Etienne MERLIN
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion